Kedrab Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Kedrab market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the rising global incidence of rabies, increased public health awareness campaigns, government initiatives aimed at rabies control, high exposure to rabid animals in rural areas, and kedrab strong market presence in key regions.

Growth during the market's forecast period can be driven by the increasing demand for post-exposure prophylaxis, expansion of healthcare infrastructure in emerging markets, greater awareness of rabies prevention, growing funding for rabies eradication programs, and rising urbanization and pet ownership rates. Key trends in the forecast period include the development of combination immunoglobulin therapies, increased adoption of Kedrab in the Asia-Pacific region, focus on cost-effective treatment solutions, the rising use of digital health tools for rabies management, and partnerships with NGOs to expand treatment access.

The growing incidence of rabies is expected to drive the kedrab market in the future. Rabies is a nearly always fatal disease caused by exposure to rabid animals, posing a significant public health challenge, especially in regions with limited access to vaccines. The increasing occurrence of rabies is driven by factors such as inadequate vaccination of domestic animals, limited availability of post-exposure prophylaxis, and the prevalence of rabies in wildlife, particularly in underserved areas. Kedrab, a human rabies immunoglobulin, provides immediate passive immunity to individuals exposed to the rabies virus, offering crucial protection until active immunity develops through vaccination. For example, in July 2024, a report from the American Veterinary Medical Association, a U.S.-based not-for-profit organization, stated that 54 U.S. jurisdictions reported 3,579 animal rabies cases in 2022, with 3,234 wildlife testing positive for rabies. Therefore, the rising incidence of rabies is driving the growth of the kedrab market.

A key trend in the kedrab market is the development of innovative solutions and securing regulatory approvals to enhance product offerings and gain a competitive edge in the industry. The recent FDA approval of Kedrab confirms its safety and effectiveness in children, supported by U.S. post-marketing clinical trial data. For instance, Kedrion Biopharma Inc., a U.S.-based biopharmaceutical company, partnered with Kamada Ltd., an Israel-based biopharmaceutical firm, to announce that the U.S. Food and Drug Administration (FDA) has approved an updated label for Kedrab (rabies immune globulin [human]), confirming its safety and effectiveness in children. This makes kedrab the first and only human rabies immune globulin (HRIG) specifically studied in a pediatric population in the U.S.

In December 2023, Kedrion Biopharma, an Italy-based biopharmaceutical company, expanded its distribution agreement with Kamada to enhance the reach of KEDRAB, a human rabies immune globulin (HRIG). This collaboration underscores Kedrion’s commitment to providing vital therapies derived from hyperimmune plasma and its strategic focus on expanding its market presence in the fight against rabies and other critical diseases. Kamada Ltd. is an Israel-based biopharmaceutical company.

Major companies operating in the kedrab market are Kamada Ltd. and Kedrion Biopharma Inc.

North America was the largest region in the kedrab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kedrab report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kedrab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kedrab is a monoclonal antibody used for the prevention and treatment of rabies after potential exposure to the virus. Derived from human sources, it provides passive immunity by neutralizing the rabies virus, helping to prevent the disease when administered post-exposure.

The primary indications of kedrab include post-exposure prophylaxis for rabies and treatment for patients exposed to suspected rabid animals. PEP for rabies involves immediate wound cleaning, administration of rabies immunoglobulin, and a series of rabies vaccinations to stop the virus from progressing after exposure. The product is available in injectable formulations and lyophilized powders for reconstitution, with administration via intramuscular or subcutaneous injection. Kedrab is distributed through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies. It is used by various healthcare providers, including hospitals, emergency departments, specialty clinics, and public health organizations.

The kedrab market research report is one of a series of new reports that provides kedrab market statistics, including kedrab industry global market size, regional shares, competitors with a kedrab market share, detailed kedrab market segments, market trends and opportunities, and any further data you may need to thrive in the kedrab industry. This kedrab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kedrab market consists of sales of kedrab-related biopharmaceutical products, including plasma-derived therapies and other related treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.